Lexaria Bioscience (LEXX) Receivables - Other (2017 - 2018)
Lexaria Bioscience's (LEXX) quarterly Receivables - Other came in at $100475.0 in Q3 2018, up 751.48% year-on-year from $11800.0 in Q3 2017, and up 751.48% quarter-over-quarter from $11800.0 in Q3 2017.
Lexaria Bioscience (LEXX) Receivables - Other (2017 - 2018) Analysis & Trends
Lexaria Bioscience has disclosed Receivables - Other across 2 years of filings, most recently posting $100475.0 for Q3 2018.
- Receivables - Other for Q3 2018 came in at $100475.0, up 751.48% year-over-year; the trailing twelve-month figure through Aug 2018 was $100475.0 (up 751.48% YoY), and the FY2018 annual result was $100475.0, up 751.48% from the prior year.
- Receivables - Other came in at $100475.0 for Q3 2018 at Lexaria Bioscience, up from $11800.0 in the prior quarter.
- In the past five years, Receivables - Other ranged from a high of $100475.0 in Q3 2018 to a low of $11800.0 in Q3 2017.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - |
| 10 | Lexaria Bioscience | 7.17 Mn | 1.65 Mn | 20,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Aug 31, 2018 | 100,475.00 |
| Aug 31, 2018 | 100,475.00 |
| Aug 31, 2017 | 11,800.00 |
| Aug 31, 2017 | 11,800.00 |